“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
Search
Launch of first veterinary vaccines produced in China
Swine vaccine Ingelvac PRRS MLV, produced by Boheringer Ingelheim veterinary vaccine manufacturing plant in Taizhou is now officially supplied to the China market.
International Women's Day
We celebrate International Women’s Day with this year’s UN Women motto being “Gender Equality Today for a Sustainable Tomorrow”
Celebrating Women in Technology
We want to elevate women in technology: empower them, affirm their potential and enable them to soar to new heights
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Our Health and Safety initiative - BE SAFE
Health and safety are of great importance to Boehringer Ingelheim.
Women in STEM 2022
Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM.
Vaccine bluetongue virus serotype 3 sheep cattle
BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.
Patient Organizations
Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
Smart Factory: Digitalizing production facilities
How our digitalized production facilities help our colleagues and patients
Supporting grooms in equestrian sports
Find out how one organization can change the lives of those who dedicate their careers to horse care.
Edda Dankmeyer
Edda Dankmeyer is our Lead of Sustainable Development Communications. She tells us where her passion for sustainability comes from, why she joined us, and how sustainable development can be a key differentiator for the company.
DiaTEC new purification technology Ingelvac CircoFLEX
Boehringer Ingelheim introduces DiaTEC, a new and proprietary purification technology for Ingelvac CircoFLEX®
Partnering with Constantia Flexibles for augmented reality
Boehringer Ingelheim partnered with Constantia Flexibles to provide an innovative packaging solution which enhances the Nutraxin packaging with augmented reality features.
Sustainable medicines that help minimize environmental impact
How we collaborate with renowned experts to lead the way in reducing solvent waste, as part of our efforts to embed sustainability into our core business.
New positive data in Phase III type 2 diabetes trial
DINAMO Phase III trial demonstrated empagliflozin significantly reduced blood sugar levels in children and adolescents with type 2 diabetes
Yamagata
The site in Yamagata, Japan, is dedicated to the production of human pharmaceutical products for the Japanese market.
preserved-heart-failure-treatment-approval-europe
preserved-heart-failure-treatment-approval-europe
emperor-reduced-chmp-positive-opinion
CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
Be At The Heart Of Every Breakthrough
Now is the time to cultivate your unique tech talent at a leading pharmaceutical company.
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Ingelheim
The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.
collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
EU approved Jardiance for type 2 diabetes in children
Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above
Research ruminant animal health well-being
Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research